Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma. (June 2015)

• Record Type: Journal Article
• Authors: Komatsu, Shuhei; Ichikawa, Daisuke; Miyamae, Mahito; Kawaguchi, Tsutomu; Morimura, Ryo; Hirajima, Shoji; Okajima, Wataru; Ohashi, Takuma; Imamura, Taisuke; Konishi, Hirotaka; Shiozaki, Atsushi; Ikoma, Hisashi; Okamoto, Kazuma; Taniguchi, Hiroki; Otsuji, Eigo
• Is Part Of: Expert opinion on biological therapy. Volume 15:Number 6(2015:Jun.)
• Page Start: 773
• Page End: 785
• Publication Date: 2015-06
• Subjects: Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1517/14712598.2015.1029914
• Languages: English
• ISSNs: 1471-2598

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Background:</italic> </bold> Recent studies have identified that microRNAs are stably detectable in plasma/serum because of their binding to specific proteins or being packaged in secretory vesicles.</p> <p> <bold> <italic>Methods:</italic> </bold> We tested miR-223 as a candidate of novel plasma biomarker in pancreatic cancer (PCa) and intraductal papillary mucinous neoplasm (IPMN).</p> <p> <bold> <italic>Results:</italic> </bold> i) miR-223 expression was significantly higher in PCa tissues (p = 0.0069) than in normal tissues. ii) Plasma miR-223 levels were significantly higher in 71 PCa patients than 67 healthy volunteers (p < 0.0001). iii) Plasma miR-223 levels were significantly reduced in postoperative samples (p = 0.0297). iv) Plasma miR-223 levels tended to discriminate the malignant potential between benign IPMN and malignant IPMN (p = 0.0963), and the progressive extent of invasiveness between malignant IPMN and pancreatic invasive ductal carcinoma (PIDC) (p = 0.0004). Multivariate logistic regression analysis revealed that a low level of plasma miR-223 was an independent risk factor for PIDC (p = 0.0012, odds ratio 7.90 [95% CI: 2.06 – 41.2]). v) There was no significant correlation between plasma miR-223 levels and the number of any blood cell types in the peripheral blood.</p> <p> <bold> <italic>Conclusion:</italic> </bold> Plasma miR-223 might be a clinically useful biomarker for screening PCa, and predicting malignant potential of IPMN and the invasiveness of PCa.</p> </abstract>